A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation

Multiple Sclerosis Journal

Volumn 19, Issue 1, 2013, Pages 59-68

  Rossi, Silvia ^a,b   Motta, Caterina ^a,b   Studer, Valeria ^a,b   Monteleone, Fabrizia ^a,b   De Chiara, Valentina ^a,b   Buttari, Fabio ^a,b   Barbieri, Francesca ^a,b   Bernardi, Giorgio ^a,b   Battistini, Luca ^b   Cutter, Gary ^c   Stüve, Olaf ^d,e   Salvetti, Marco ^f   Centonze, Diego ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF ALABAMA   (United States)

^d VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

^f Dermatologic Department S Andrea Hospital   (Italy)

Author keywords

Apoptosis; CIRIS; lymphocytosis; rebound; relapse

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; PROTEIN KINASE B; REBIF 44; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL SURVIVAL; DISEASE EXACERBATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; GENETIC VARIABILITY; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENCE RISK; RECURRENT DISEASE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84872289860     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512448106     Document Type: Article

References (44)

1. Comi G. Treatment of multiple sclerosis: role of natalizumab. Neurol Sci. 2009 ; 30: S155 - S158
2. Coyle PK. The role of natalizumab in the treatment of multiple sclerosis. Am J Manag Care. 2010 ; 16: S164 - S170
3. Langer-Gould A, Steinman L. Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab. Curr Neurol Neurosci Rep. 2006 ; 6: 253-258
4. Lindå H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med. 2009 ; 361: 1081-1087
5. Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010 ; 9: 438-446
6. Steiner I. PML: underdiagnosed in MS patients on natalizumab. Lancet Neurol. 2010 ; 9: 564
7. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010 ; 68: 295-303
8. Fox RJ, Kappos L. Is natalizumab overshooting its rebound?. Neurology. 2008 ; 70: 1073-1074
9. Vellinga MM, Castelijns JA, Barkhof F, et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology. 2008 ; 70: 1150-1151
10. Berger JR, Centonze D, Comi G, et al. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol. 2010 ; 68: 409-411
11. Killestein J, Vennegoor A, Strijbis EM, et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol. 2010 ; 68: 392-395
12. West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting?. Ann Neurol. 2010 ; 68: 395-399
13. Havla J, Gerdes LA, Meinl I, et al. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol. 2011 ; 258: 1665-1669
14. Kaufman MD, Lee R, Norton H. Course of relapsing-remitting multiple sclerosis before, during and after natalizumab. Mult Scler. 2011 ; 17: 490-494
15. Kroner A, Mehling M, Hemmer B, et al. A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol. 2005 ; 58: 50-57
16. Huck K, Feyen O, Niehues T, et al. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest. 2009 ; 119: 1350-1358
17. Morton LM, Purdue MP, Zheng T, et al. Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiol Biomarkers Prev. 2009 ; 18: 1259-1270
18. Brognard J, Clark AS, Ni Y, et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001 ; 61: 3986-3997
19. Emamian ES, Hall D, Birnbaum MJ, et al. Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia. Nat Genet. 2004 ; 36: 131-137
20. Shen M, Lan Q, Zhang L, et al. Polymorphisms in genes involved in DNA double-strand break repair pathway and susceptibility to benzene-induced hematotoxicity. Carcinogenesis. 2006 ; 27: 2083-2089
21. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007 ; 129: 1261-1274
22. Hutz JE, Manning WA, Province MA, et al. Genomewide analysis of inherited variation associated with phosphorylation of PI3K/AKT/mTOR signaling proteins. PLos One. 2011 ; 6: e24873
23. Pu X, Hildebrandt MA, Lu C, et al. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer. 2011 ; 71: 82-88
24. Schatz JH, Wendel HG. Targeted cancer therapy: What if the driver is just a messenger?. Cell Cycle. 2011 ; 10: 3830-3833
25. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol. 2005 ; 58: 840-846
26. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 ; 33: 1444-1452
27. Jurinke C, van den Boom D, Cantor CR, et al. The use of MassARRAY technology for high throughput genotyping. Adv Biochem Eng Biotechnol. 2002 ; 77: 57-74
28. Hasan SK, Buttari F, Ottone T, et al. Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes. Neurology. 2011 ; 76: 1059-1065
29. Mori F, Ribolsi M, Kusayanagi H, et al. Genetic variants of the NMDA receptor influence cortical excitability and plasticity in humans. J Neurophysiol. 2011 ; 106: 1637-1643
30. Putzki N, Baranwald MK, Tettenborn B, et al. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells. Eur Neurol. 2010 ; 63: 31-37
31. Frisullo G, Iorio R, Plantone D, et al. CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment. Mult Scler. 2011 ; 17: 556-566
32. Skarica M, Eckstein C, Whartenby KA, et al. Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. J Neuroimmunol. 2011 ; 235: 70-76
33. Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006 ; 59: 743-747
34. Stüve O, Marra CM, Bar-Or A, et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol. 2006 ; 63: 1383-1387
35. Schiess N, Calabresi PA. Natalizumab: bound to rebound?. Neurology. 2009 ; 72: 392-393
36. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011 ; 76: 1858-1865
37. Lenhard T, Biller A, Mueller W, et al. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?. Neurology. 2010 ; 75: 831-833
38. Perumal J, Caon C, Hreha S, et al. Post-natalizumab rebound: a CNS immune reconstitution syndrome (CIRIS). Neurology. 2010 ; 74: A558
39. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2011 ; 68: 186-191
40. Silvy A, Altevogt P, Mondiere P, et al. A role for the VLA-4 integrin in the activation of human memory B cells. Eur J Immunol. 1997 ; 27: 2757-2764
41. Neumann F, Zohren F, Haas R. The role of natalizumab in hematopoietic stem cell mobilization. Expert Opin Biol Ther. 2009 ; 9: 1099-1106
42. Lindberg R, Achtnichts L, Hoffmann F, et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol. 2008 ; 194: 153-164
43. Ransohoff RM. Natalizumab, multiple sclerosis, and primary central nervous system lymphoma: enigma, wrapped in mystery, enclosed in conundrum. Ann Neurol. 2009 ; 66: 259-261
44. Ismail A, Kemp J, Sharrack B. Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis. J Neurol. 2009 ; 256: 1771-1772